Cargando…

Oral Anticoagulant Use in Elderly Japanese Patients With Non-Valvular Atrial Fibrillation　― Subanalysis of the ANAFIE Registry ―

Background: Oral anticoagulants (OACs) are effective in preventing stroke in patients with atrial fibrillation (AF), but are challenging for elderly patients because of the higher risk of bleeding complications. Methods and Results: The ANAFIE Registry is a prospective multicenter observational stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akao, Masaharu, Shimizu, Wataru, Atarashi, Hirotsugu, Ikeda, Takanori, Inoue, Hiroshi, Okumura, Ken, Koretsune, Yukihiro, Tsutsui, Hiroyuki, Toyoda, Kazunori, Hirayama, Atsushi, Yasaka, Masahiro, Yamashita, Takeshi, Yamaguchi, Takenori, Teramukai, Satoshi, Kimura, Tetsuya, Kaburagi, Jumpei, Takita, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932811/ https://www.ncbi.nlm.nih.gov/pubmed/33693180 http://dx.doi.org/10.1253/circrep.CR-20-0082

Ejemplares similares

Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry
por: Mizokami, Yuji, et al.
Publicado: (2020)

Background characteristics and anticoagulant usage patterns of elderly non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective, multicentre, observational cohort study in Japan
por: Yasaka, Masahiro, et al.
Publicado: (2021)

High prevalence of masked uncontrolled morning hypertension in elderly non‐valvular atrial fibrillation patients: Home blood pressure substudy of the ANAFIE Registry
por: Kario, Kazuomi, et al.
Publicado: (2020)

Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE Registry
por: Suzuki, Shinya, et al.
Publicado: (2023)

Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry
por: Yamashita, Takeshi, et al.
Publicado: (2021)

Renal Function and Clinical Outcomes Among Elderly Patients With Nonvalvular Atrial Fibrillation From ANAFIE
por: Shimizu, Wataru, et al.
Publicado: (2023)

Coagulation Biomarkers and Clinical Outcomes in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Subcohort Study
por: Koretsune, Yukihiro, et al.
Publicado: (2023)

Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry
por: Okumura, Ken, et al.
Publicado: (2022)

Impact of cognitive impairment on clinical outcomes in elderly patients with atrial fibrillation: ANAFIE Registry
por: Nagata, Ken, et al.
Publicado: (2023)

Anticoagulant therapy and home blood pressure-associated risk for stroke/bleeding events in elderly patients with non-valvular atrial fibrillation: the sub-cohort study of ANAFIE registry
por: Kario, Kazuomi, et al.
Publicado: (2023)

Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry
por: Yoshimoto, Takeshi, et al.
Publicado: (2022)

Impact of glycated hemoglobin on 2-year clinical outcomes in elderly patients with atrial fibrillation: sub-analysis of ANAFIE Registry, a large observational study
por: Terauchi, Yasuo, et al.
Publicado: (2023)

Home Blood Pressure Can Predict the Risk for Stroke/Bleeding Events in Elderly Patients With Nonvalvular Atrial Fibrillation From the ANAFIE Registry
por: Kario, Kazuomi, et al.
Publicado: (2022)

Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry
por: Shiozawa, Masayuki, et al.
Publicado: (2023)

Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2018)

Impact of heart rate on adverse events in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2022)

Predictive ability of visit-to-visit blood pressure indices for adverse events in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2023)

Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2020)

Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study
por: Koretsune, Yukihiro, et al.
Publicado: (2019)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
por: Inoue, Hiroshi, et al.
Publicado: (2016)

Impact of Blood Pressure Visit‐to‐Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J‐RHYTHM Registry
por: Kodani, Eitaro, et al.
Publicado: (2020)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
por: Ishii, Mitsuru, et al.
Publicado: (2022)

Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Nakamura, Mashio, et al.
Publicado: (2023)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J’xactly Study
por: Yamada, Norikazu, et al.
Publicado: (2023)

Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial
por: Yoshida, Tetsuro, et al.
Publicado: (2022)

Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis
por: Tanaka, Nobuaki, et al.
Publicado: (2022)

Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
por: Abe, Ichitaro, et al.
Publicado: (2021)

Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On‐label Doses of Apixaban: J‐ELD AF Registry Subanalysis
por: Okada, Masato, et al.
Publicado: (2021)

Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE
por: Shinohara, Tetsuji, et al.
Publicado: (2020)

Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation: Sub-analysis of the EXPAND Study
por: Uchiyama, Shinichiro, et al.
Publicado: (2018)

Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study
por: Atarashi, Hirotsugu, et al.
Publicado: (2021)

Clinical phenotypes of patients with non-valvular atrial fibrillation as defined by a cluster analysis: A report from the J-RHYTHM registry
por: Watanabe, Eiichi, et al.
Publicado: (2021)

One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis)
por: Awano, Nobuyasu, et al.
Publicado: (2022)

Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
por: Koretsune, Yukihiro, et al.
Publicado: (2017)

Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE–AF Randomized Clinical Trial
por: Kuroda, Masaru, et al.
Publicado: (2022)

Impact of baseline blood pressure on adverse outcomes in Japanese patients with non-valvular atrial fibrillation: the J-RISK AF
por: Kodani, Eitaro, et al.
Publicado: (2022)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4np77me4psq7m6lardr1e54cdk